FDA Approves Xermelo for Carcinoid Syndrome Diarrhea

Share this content:
FDA Approves Xermelo for Carcinoid Syndrome Diarrhea
FDA Approves Xermelo for Carcinoid Syndrome Diarrhea

WEDNESDAY, March 1, 2017 (HealthDay News) -- Xermelo (telotristat ethyl) tablets have been approved by the U.S. Food and Drug Administration to treat adults with carcinoid syndrome diarrhea.

Xermelo, taken orally three times daily with food, in combination with somatostatin analog therapy, is designed to inhibit production of serotonin by carcinoid tumors, the FDA said.

The drug was evaluated in clinical studies involving 90 adults with carcinoid syndrome diarrhea, comparing results from those treated with the drug versus a placebo. The agency warned that people given a higher-than-recommended dose developed severe constipation, and one required hospitalization. Any Xermelo user who develops severe constipation or abdominal pain should stop the drug and contact a doctor, the FDA said.

"Today's approval will provide patients whose carcinoid syndrome diarrhea is not adequately controlled with another treatment option," Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in a statement.

Xermelo is produced by Lexicon Pharmaceuticals, based in Woodlands, Texas.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA Warns of Possible Heart Risks Linked to Clarithromycin

FDA Warns of Possible Heart Risks Linked to ...

Agency advising doctors to consider prescribing other antibiotics to patients with coronary heart disease

Artificial Intelligence May Help Prevent Physician Burnout

Artificial Intelligence May Help Prevent Physician Burnout

Many potential uses for AI, including improving searches and documentation, selecting treatment

Benzodiazepine Use Declining in Older Adults

Benzodiazepine Use Declining in Older Adults

Findings based on assessment of incidence, prevalence of use in three countries from 2010-2016

is free, fast, and customized just for you!

Already a member?

Sign In Now »